BiotechTube
LEX Diagnostics

LEX Diagnostics

Cambridge, United Kingdom· Est.
lexdiagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

LEX Diagnostics is a private, Cambridge-UK company founded in 2020 as a spin-out from TTP Group, focusing on revolutionizing point-of-care diagnostics with its ultra-fast PCR technology. The company achieved a major milestone in February 2026 with FDA 510(k) clearance and CLIA waiver for its LEX VELO Respiratory Test for Flu A, Flu B, and COVID-19. With a compact, user-friendly system designed for waived settings, LEX is positioned to address the critical need for rapid, accurate molecular testing outside central labs. The company is backed by TTP Group and a significant third-party investor, building a team to commercialize its platform and expand its test menu.

Infectious Disease

Technology Platform

Ultra-fast PCR thermal cycling technology enabling swab-to-result in under 10 minutes in a fully automated, CLIA-waived, compact point-of-care system.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

The massive, growing market for decentralized, rapid molecular diagnostics in CLIA-waived settings like pharmacies and doctor's offices presents a major opportunity.
Expanding the test menu from respiratory to STI testing can access larger, recurring revenue streams and meet significant unmet needs in sexual health.

Risk Factors

The company faces intense competition from established players in the point-of-care molecular space and must execute flawlessly on its commercial launch as a new entrant.
Future growth depends on the timely and successful regulatory clearance of its pipeline tests, which carries inherent development and approval risk.

Competitive Landscape

LEX VELO competes in the fast POC molecular segment against systems like Abbott's ID NOW (15 mins), Cepheid's Xpert Xpress (30 mins), and BioFire's FilmArray (45 mins-1 hour). Its key claimed advantages are superior speed (6-10 mins) and a fully automated, CLIA-waived workflow, but it must compete against these deeply entrenched platforms with extensive test menus and sales networks.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →